Changes in Hospital-Based Flu A/B, RSV Antigen Testing

SUBJECT: Changes in Flu A/B, RSV antigen testing – Transition to Cepheid SARS-COV-2-Only and SARS-COV-2, Flu A, Flu B, and RSV PCR (4-Plex) for hospital-based testing

DESCRIPTION: The VMC Laboratory will be discontinuing the following tests:  Flu A/B antigen, RSV antigen, and SARS-COV-2 PCR performed on the Aries platform. Testing for these respiratory pathogens is transitioning to the Cepheid platform and will include a standalone SARS-COV-2 PCR and a 4-plex PCR that will detect SARS-COV-2, Flu A/B, and RSV.

WHY: Cepheid utilizes a molecular methodology that provides greater sensitivity and specificity compared to traditional antigen-based methods, without limitations related to the patient’s age or co-infections. Viral respiratory syndromes are difficult to distinguish clinically. So instead of testing for respiratory viruses individually, the 4-plex test offers a more comprehensive and efficient test solution covering the most common respiratory viruses. 

WHEN: Effective 2/11/2025, Cepheid SARS-COV-2-only and 4-Plex testing will be available options for respiratory pathogen detection.

Review this document for testing options, specimen requirements, results reporting and other important details.